A fight to not just treat, but to cure cancer.

Lona Biotherapeutics is a pioneering biotechnology company with a focus on revolutionising cancer treatment through innovative T-cell receptor-engineered T cell (TCR-T) therapies. Founded by a diverse team of experts, including leading researchers in cancer immunotherapy, serial entrepreneurs, and professors in data science and AI technology, the company is at the forefront of personalised medicine.

Groundbreaking Research

The scientific foundation of Lona Biotherapeutics is rooted in over two decades of rigorous research in TCR-Engineered T Cells. Our founding partners have made significant contributions to the field, including the development of new methods for genetically engineering patients' T cells into tumour-specific T cells. This research has shown promising results in treating certain solid tumours, including metastatic melanoma, synovial sarcoma, and multiple myeloma.

Integration of AI Technology

In 2018, we began the integration of cutting-edge AI technology with the foundational research conducted in Xi'an. This innovative approach, known as ImmunoAI, aims to streamline the research, development, and production processes. The application of AI technology not only enhances the effectiveness of our therapies but also makes them more accessible by reducing costs.

Global Expansion and Clinical Trials

As we near the completion of our clinical trials in China, Lona Biotherapeutics is expanding its global footprint. We are in the process of opening an office in Singapore and establishing labs and offices in London. These new locations will serve as pivotal hubs for securing European and U.S. approvals for our groundbreaking therapies.

Multidisciplinary Team

Our team is a blend of experts from various fields. In addition to our founding partners who bring in-depth knowledge of cancer immunotherapy, we have specialists in data science and AI technology. Their expertise is instrumental in optimising processes, thereby making our treatments not only more effective but also more affordable.

The Future

Lona Biotherapeutics is committed to delivering more effective, personalised, and cost-efficient treatments to patients in need. As we continue to grow and evolve, we remain focused on our mission to transform the landscape of cancer treatment through innovation, research, and global collaboration.